Knowledge of the cellular- and synaptic-mechanisms underlying cell body hyperexcitability produced by the FMRP absence is relevant to better understand the clinical features of FXS and could provide a potentially rich source of pharmacological and genetic therapies for treatment of this neurological disorder. This evidence concerns the gene FMR1 and fragile X syndrome.